Veritas Capital, a leading investor at the intersection of technology and government, announced that one of its affiliates has entered into a definitive agreement to acquire a majority stake in Global Healthcare Exchange, a leading supply chain software platform powering mission-critical connectivity between healthcare providers and suppliers. Veritas will join existing GHX shareholders Temasek and Warburg Pincus to support the acceleration of the Company’s growth strategy.
GHX was built to connect healthcare providers and suppliers, helping to ensure that the right products are delivered to the right place at the right time. Healthcare supply chains have become more costly, operationally complex, and inefficient, limiting the ability of providers and suppliers alike to derive actionable insights from the data created at every touchpoint. GHX addresses these inefficiencies through one seamless platform that digitizes and automates highly complex, dynamic healthcare supply chain processes, and it continues to innovate alongside customers to deliver meaningful value. Today, GHX’s solutions are more essential than ever, enhancing supply chain resiliency, reducing waste, and ultimately improving delivery of patient care.
GHX serves Gartner’s top 25 U.S. healthcare systems and the top 30 medical-surgical suppliers globally among its extensive network of customers. Through its cloud-based solutions, AI-driven automation, and intelligent decision support capabilities, GHX has delivered over $27 billion of savings in the last three years alone, in addition to supporting its customers’ efforts to enable better clinical care.
Health Technology Insights: CareTrust Acquires $142 Million Mid-Atlantic Nursing Portfolio
Veritas’ investment will accelerate GHX’s vision of creating a more efficient, resilient, and interconnected system. Through its innovative platform, the Company brings together the industry’s largest unified data core, spanning product, vendor, transactional, clinical and operational domains. With accelerated AI investments, GHX will be positioned to help organizations leverage their data to simplify workflows, generate actionable insights, automate decision-making, and ultimately improve delivery of care.
“This investment enables us to move faster and think bigger about building a more resilient, AI-enabled supply chain,” said Tina Vatanka Murphy, President and CEO of GHX. “Veritas recognizes our unique role in facilitating better, more affordable patient care, and they bring deep experience scaling healthcare technology companies that matter. This partnership will help us further invest in product innovation, pursue both organic and inorganic growth, and amplify our AI-powered supply chain strategy. It is a strong affirmation of our strategy, our people and the opportunity ahead.”
Health Technology Insights: Incyte Reports Positive Topline Results for Tafasitamab in DLBCL
“We have long admired the vital role GHX plays in lowering the cost of care and enabling resilient supply chains,” said Ramzi Musallam, CEO and Managing Partner of Veritas Capital. “We see many parallels between GHX and prior scaled healthcare technology investments by Veritas at the intersection of mission-critical data and real-time decision making. We look forward to leveraging these experiences to support Tina and her team on their journey to reimagine the healthcare supply chain, with an overarching common goal of driving better patient outcomes.”
Ravi Lambah, Head, Strategic Initiatives at Temasek, added, “Since 2017, we have supported GHX through key phases of transformation, strengthening its position as a leading integrated, data‑driven platform. Veritas’ acquisition of a majority stake extends the strong partnership we have had with Warburg Pincus and supports the next stage of GHX’s growth. This is aligned with our conviction that digitization underpins stronger and more resilient healthcare supply chains.”
“Our conviction in GHX and the value of our partnership is as strong as ever, and Veritas’ investment is a further confirmation of the enduring value that GHX provides across the healthcare industry,” said Adam Krainson, Managing Director at Warburg Pincus. “We are pleased to continue our work with the Company to help expand its reach, serving customers around the world.”
The transaction is expected to close in the first quarter of 2026, subject to customary closing conditions, including regulatory approvals. Financial terms were not disclosed.
Evercore served as financial advisor to GHX. Cleary Gottlieb Steen & Hamilton LLP served as legal counsel to GHX and Temasek. Gibson, Dunn & Crutcher LLP is acting as legal counsel to Veritas. Kirkland & Ellis LLP is acting as legal counsel to Warburg Pincus.
Health Technology Insights: Natera Launches 21-Gene Fetal Focus Single-Gene NIPT
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
